Anagram Therapeutics, Inc.
David Brown has extensive work experience in the pharmaceutical industry. David is currently the SVP Product Development at Anagram Therapeutics, Inc. Prior to that, they worked as the VP Technical Operations at Alcresta Therapeutics from 2015 to 2021. Before that, they held a similar role at Stealth BioTherapeutics from 2014 to 2015. From 2011 to 2014, David worked at Patheon as an Account Executive and later as a Business Development Manager. David also held the position of Associate Director of Contract Manufacturing at Alnara Pharmaceuticals from 2009 to 2011, and at Altus Pharmaceuticals from 2008 to 2009. David's earlier roles include Manager of Process Development at Alkermes from 2001 to 2008, Senior Process Engineer at Ortec International, Inc. from 1998 to 2000, and Process Engineer at Genzyme from 1993 to 1998.
David Brown attended Northeastern University from 1988 to 1993, where they earned a Bachelor of Science degree in Chemical Engineering.
This person is not in any teams
Anagram Therapeutics, Inc.
Anagram is a clinical stage company leveraging proprietary enzyme technologies and expertise in gastrointestinal diseases to solve complex problems and advance a pipeline of products that can make a life-changing impact for people and their families living with cystic fibrosis and other rare diseases. Malabsorption syndromes and nutrient metabolism disorders prevent the body from properly processing or absorbing certain fats, sugars, proteins, vitamins or other key nutrients. ANG003, Anagram’s lead product is intended for the treatment of malabsorption and exocrine pancreatic insufficiency and is a new class of broad-spectrum digestive enzyme replacement therapy.